L-2D - Off-label Use of Potential Pharmacological Treatment for COVID-19: An Intensive Pharmacovigilance in Peru
Location: L-2
Pharmacovigilance
Tuesday, Aug 24th
1:45 PM – 3:30 PM US Eastern Time
OP-15C - Comparing the Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients Receiving Tofacitinib and TNF Inhibitors in Taiwan
Location: OP-15
Pharmacovigilance
Tuesday, Aug 24th
3:30 PM – 4:45 PM US Eastern Time
SP02B - Active Surveillance of Hemovigilance in a Tertiary Care Teaching Hospital: A Developing Country Scenario
Location: SP02
Pharmacovigilance
Tuesday, Aug 24th
3:30 PM – 4:45 PM US Eastern Time
SP04D - Challenges and Recommendations in Understanding National Guidance and Marketing Authorization Holder Experiences for Implementing Additional Risk Minimization Measures in the European Union and the United Kingdom
Location: SP04
Pharmacovigilance
Tuesday, Aug 24th
3:30 PM – 4:45 PM US Eastern Time
SP08B - Development of a Tool for Detecting Patient-level Symptoms in Relation with Medications Using Disease Blogs on the Internet
Location: SP08
Pharmacovigilance
Tuesday, Aug 24th
5:15 PM – 6:30 PM US Eastern Time
SP10G - COLCHICINE AND cyp3a4/p-gp INHIBITORS INTERACTION SIGNAL DETECTION USING FAERS
Location: SP10
Pharmacovigilance
Tuesday, Aug 24th
5:15 PM – 6:30 PM US Eastern Time
SP10H - Acute Generalized Exanthematous Pustulosis (AGEP): Exploratory Analysis on Drug Combinations
Location: SP10
Pharmacovigilance
Tuesday, Aug 24th
5:15 PM – 6:30 PM US Eastern Time
SP17B - Pfizer-biontech Coronavirus Vaccine and the Risk of Anaphylaxis
Location: SP17
Pharmacovigilance
Wednesday, Aug 25th
11:45 AM – 1:30 PM US Eastern Time
OP-5C - Impact of COVID-19 Social Distance Restrictions on Hospital Encounters Due to Injury by Poisoning or Toxicity of Medications or Non-medicinal Substances
Location: OP-05
Pharmacovigilance
Wednesday, Aug 25th
3:00 PM – 4:30 PM US Eastern Time
PP-01F - Predictors of Severe COVID-19 Outcome in Patients with Rheumatoid Arthritis
